No Data
Sarepta Therapeutics to Present New Data From Its Neuromuscular Portfolio at 2024 World Muscle Society Congress
Sarepta Therapeutics Price Target Maintained With a $152.00/Share by Cantor Fitzgerald
Cantor Fitzgerald Maintains Sarepta Therapeutics(SRPT.US) With Hold Rating, Maintains Target Price $152
Cantor Fitzgerald analyst Kristen Kluska maintains $Sarepta Therapeutics(SRPT.US)$ with a hold rating, and maintains the target price at $152.According to TipRanks data, the analyst has a success
Cantor Fitzgerald Sticks to Their Hold Rating for Sarepta Therapeutics (SRPT)
Implied Volatility Surging for Sarepta Therapeutics (SRPT) Stock Options
10 Health Care Stocks With Whale Alerts In Today's Session